Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantRestricted Stock Unit · Derivative | 2,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,219 Underlying: Common Stock · 2,524 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F9 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 25,140 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · derivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,140 Underlying: Common Stock · 25,140 shares Expires 2028-02-13 F9 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Tax withholdingCommon Stock | 903 | $178.26 | $160,968.78 |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,040 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 629 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 726 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008871 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 14 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,877 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F11 · price: No applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 13 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,336 Underlying: Common Stock · 737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F11 · price: No applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 472 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 12 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,073 Underlying: Common Stock · 472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F11 · price: No applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 403 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 11 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,545 Underlying: Common Stock · 403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F11 · price: No applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 10 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,948 Underlying: Common Stock · 544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F11 · price: No applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 2,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 9 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,492 Underlying: Common Stock · 2,524 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F11 · price: No applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 8 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F11 · price: No applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 25,140 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 7 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,140 Underlying: Common Stock · 25,140 shares Expires 2028-02-13 F11 · price: No applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Tax withholdingCommon Stock | 778 | $178.26 | $138,686.28 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 6 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,760 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 5 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 4 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 472 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:01 UTC |
MAZELSKY JONATHAN JAYExecutive Vice President
|
Exercise / conversionCommon Stock | 544 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 29, 2017. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774 Underlying: Common Stock · 1,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,548 Underlying: Common Stock · 2,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 90,816 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,816 Underlying: Common Stock · 90,816 shares Expires 2028-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 1,828 | $178.26 | $325,859.28 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,218 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 1,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 2,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 23:08 UTC |
Kingsley Lawrence DDirector
|
PurchaseCommon Stock | 1,000 | $178.05 | $178,045.00 |
DisclosureSEC source: 0001140361-18-008858 · doc1.xml · nonDerivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,558 Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:30 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,880 | Not disclosed Strike: $53.19 | Not disclosed |
DisclosureSEC source: 0001140361-18-007309 · doc1.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,880 Underlying: Common Stock · 1,880 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests in five equal annual installments, beginning on January 1, 2015. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:30 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 1,880 | $53.19 | $99,987.80 |
DisclosureSEC source: 0001140361-18-007309 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · derivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 4,000 | $175.34 | $701,356.80 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $175.0201 to a high of $176.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 4,000 | $38.80 | $155,180.00 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:02 UTC |
Claflin Bruce L.Director
|
PurchaseCommon Stock | 1,000 | $179.58 | $179,580.00 |
DisclosureSEC source: 0001140361-18-006393 · doc1.xml · nonDerivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 1,883 | $179.27 | $337,559.76 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $179.06 to a high of $179.58 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 4,912 | $178.36 | $876,082.71 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,060,995 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $178.0101 to a high of $178.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 11,205 | $177.63 | $1,990,383.37 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,907 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $177.01 to a high of $178.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · derivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 600 | $179.71 | $107,826.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: Represents the weighted average sales price of the shares sold ranging from a low of $179.33 to a high of $180.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 2,400 | $178.73 | $428,944.08 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,712 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: Represents the weighted average sales price of the shares sold ranging from a low of $178.13 to a high of $179.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 3,800 | $177.62 | $674,945.74 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $177.24 to a high of $178.18 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 3,600 | $176.87 | $636,746.04 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,912 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $176.255 to a high of $177.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 2,400 | $175.67 | $421,603.92 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,512 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: Represents the weighted average sales price of the shares sold ranging from a low of $175.23 to a high of $176.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 5,200 | $174.86 | $909,295.92 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,912 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $174.22 to a high of $175.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,602 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-005648 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,602 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.